BRPI0823228A2 - moduladores de cassete de ligação a atp. - Google Patents

moduladores de cassete de ligação a atp.

Info

Publication number: BRPI0823228A2
Authority: BR; Brazil
Prior art keywords: modulators; atp binding; binding cassette; cassette; atp
Prior art date: 2008-11-06

Application number

BRPI0823228A

Other languages

English (en)

Inventor

Brian Bear

Frederick Van Goor

Jason Mccartney

Jinglan Zhou

Mark T Miller

Mehdi Michel Djamel Numa

Peter D J Grootenhuis

Sara S Hadida Ruah

Original Assignee

Vertex Pharmaceuticals Incorporarted

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-06

Filing date

2008-11-12

Publication date

2016-10-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40933810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0823228(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-11-12 Application filed by Vertex Pharmaceuticals Incorporarted filed Critical Vertex Pharmaceuticals Incorporarted

2016-10-11 Publication of BRPI0823228A2 publication Critical patent/BRPI0823228A2/pt

2020-10-20 Publication of BRPI0823228B1 publication Critical patent/BRPI0823228B1/pt

2021-05-25 Publication of BRPI0823228B8 publication Critical patent/BRPI0823228B8/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Neurology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0823228A 2008-11-06 2008-11-12 moduladores de cassete de ligação a atp BRPI0823228B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US11214508P	2008-11-06	2008-11-06
US11215208P	2008-11-06	2008-11-06
US61/112,152		2008-11-06
US61/112,145		2008-11-06
PCT/US2008/012689 WO2010053471A1 (en)	2008-11-06	2008-11-12	Modulators of atp-binding cassette transporters

Publications (3)

Publication Number	Publication Date
BRPI0823228A2 true BRPI0823228A2 (pt)	2016-10-11
BRPI0823228B1 BRPI0823228B1 (pt)	2020-10-20
BRPI0823228B8 BRPI0823228B8 (pt)	2021-05-25

Family

ID=40933810

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0823228A BRPI0823228B8 (pt)	2008-11-06	2008-11-12	moduladores de cassete de ligação a atp

Country Status (31)

Country	Link
EP (2)	EP2365972B1 (pt)
JP (4)	JP5600322B2 (pt)
KR (3)	KR20160013251A (pt)
CN (2)	CN102272127A (pt)
AU (1)	AU2008363828B2 (pt)
BR (1)	BRPI0823228B8 (pt)
CA (1)	CA2742821C (pt)
CL (1)	CL2011001027A1 (pt)
CY (2)	CY1116067T1 (pt)
DK (1)	DK2365972T3 (pt)
ES (1)	ES2532753T3 (pt)
FR (1)	FR19C1017I2 (pt)
HK (1)	HK1216526A1 (pt)
HR (1)	HRP20150288T1 (pt)
HU (1)	HUS1900015I1 (pt)
IL (3)	IL212737A (pt)
LT (1)	LTC2365972I2 (pt)
LU (1)	LUC00110I2 (pt)
ME (1)	ME02105B (pt)
MX (2)	MX357497B (pt)
NL (1)	NL300984I9 (pt)
NO (1)	NO2019015I1 (pt)
NZ (2)	NZ609962A (pt)
PL (1)	PL2365972T3 (pt)
PT (1)	PT2365972E (pt)
RS (1)	RS53868B1 (pt)
RU (1)	RU2013157877A (pt)
SI (1)	SI2365972T1 (pt)
UA (1)	UA121188C2 (pt)
WO (1)	WO2010053471A1 (pt)
ZA (1)	ZA201103883B (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2881078C (en)	2004-06-24	2018-10-02	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
PT2404919E (pt)	2005-11-08	2013-10-22	Vertex Pharma	Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
LT1993360T (lt)	2005-12-28	2017-06-12	Vertex Pharmaceuticals Incorporated	N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
JP5420395B2 (ja)	2006-04-07	2014-02-19	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセット輸送体の調節剤
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
EP2164840A2 (en)	2007-05-09	2010-03-24	Vertex Pharmaceuticals Incorporated	Modulators of cftr
HUE049642T2 (hu)	2007-12-07	2020-09-28	Vertex Pharma	3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
CA2989620C (en)	2007-12-07	2022-05-03	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CA2716109C (en)	2008-02-28	2016-07-19	Vertex Pharmaceuticals Incorporated	Heteroaryl derivatives as cftr modulators
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
UA104876C2 (uk) *	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
KR20160013251A (ko) *	2008-11-06	2016-02-03	버텍스 파마슈티칼스 인코포레이티드	Ａｔｐ-결합 카세트 수송자의 조절자
SI3330255T1 (sl)	2009-03-20	2021-03-31	Vertex Pharmaceuticals Incorporated	Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
EP2563778B1 (en) *	2010-03-25	2016-08-24	Vertex Pharmaceuticals Incorporated	Crystalline form of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2900353T3 (es)	2010-04-07	2022-03-16	Vertex Pharma	Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
WO2011133953A1 (en) *	2010-04-22	2011-10-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
NZ603044A (en) *	2010-04-22	2015-08-28	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
RU2569678C2 (ru)	2010-04-22	2015-11-27	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения циклоалкилкарбоксамидо-индольных соединений
NZ603042A (en) *	2010-04-22	2015-02-27	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
JP2013536231A (ja) *	2010-08-23	2013-09-19	バーテックスファーマシューティカルズインコーポレイテッド	（ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
CA2852991C (en) *	2011-11-08	2019-12-31	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
NZ727015A (en)	2012-01-25	2017-12-22	Vertex Pharma	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2819670B1 (en)	2012-02-27	2026-05-20	Vertex Pharmaceuticals Incorporated	Pharmaceutical Composition and Their Administration
AU2013290444B2 (en)	2012-07-16	2018-04-26	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
EP2970468B1 (en)	2013-03-13	2021-07-07	Novartis AG	Notch2 binding molecules for treating respiratory diseases
EP2968323A4 (en)	2013-03-13	2016-12-14	Flatley Discovery Lab	PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
CA2930199C (en)	2013-11-12	2022-10-25	Vertex Pharmaceuticals Incorporated	Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
PL3925607T5 (pl)	2014-04-15	2026-06-01	Vertex Pharmaceuticals Incorporated	Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
EP2932966A1 (en)	2014-04-16	2015-10-21	Novartis AG	Gamma secretase inhibitors for treating respiratory diseases
ES2773142T3 (es)	2014-05-12	2020-07-09	Verona Pharma Plc	Nuevo tratamiento
GB201415381D0 (en)	2014-08-29	2014-10-15	Algipharma As	Inhalable powder formulations of alginate oligomers
TW202140422A (zh)	2014-10-06	2021-11-01	美商維泰克斯製藥公司	囊腫纖維化症跨膜傳導調節蛋白之調節劑
CA2963945C (en)	2014-10-07	2023-01-10	Vertex Pharmaceuticals Incorporated	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
HUE055423T2 (hu)	2014-11-18	2021-11-29	Vertex Pharma	Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
EA201791500A1 (ru)	2014-12-31	2018-01-31	Оспекс Фармасьютикалз, Инк.	Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости
GB201504878D0 (en)	2015-03-23	2015-05-06	Algipharma As	Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
US10196384B2 (en)	2015-03-31	2019-02-05	Vertex Pharmaceuticals (Europe) Limited	Deuterated CFTR modulators
CN105153106B (zh) *	2015-09-02	2017-08-25	阜新奥瑞凯新材料有限公司	一种2,2‑二氟胡椒酸甲酯的制备方法
GB201517639D0 (en)	2015-10-06	2015-11-18	Algipharma As	Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
US10047077B2 (en)	2016-04-13	2018-08-14	Skyline Antiinfectives, Inc.	Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
JP6601365B2 (ja)	2016-07-27	2019-11-06	株式会社デンソー	制御システム
GEP20217329B (en)	2016-09-30	2021-12-10	Vertex Pharma	Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EA202192783A1 (ru) *	2016-12-09	2022-02-24	Вертекс Фармасьютикалз Инкорпорейтед	Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
MA54105A (fr)	2017-06-08	2021-09-15	Vertex Pharma	Méthodes de traitement de la fibrose kystique
IL272032B2 (en)	2017-07-17	2026-04-01	Vertex Pharma	Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and
MA49752A (fr)	2017-08-02	2021-04-21	Vertex Pharma	Procédés de préparation de composés de pyrrolidine
US10988454B2 (en) *	2017-09-14	2021-04-27	Abbvie Overseas S.À.R.L.	Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CA3078893A1 (en)	2017-10-19	2019-04-25	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of cftr modulators
KR102716244B1 (ko)	2017-12-08	2024-10-14	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
RS64018B1 (sr)	2018-02-15	2023-03-31	Vertex Pharma	Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade
WO2019200246A1 (en)	2018-04-13	2019-10-17	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN111763198B (zh) *	2019-04-01	2021-09-07	新发药业有限公司	一种5-取代环丙基甲酰氨基吲哚衍生物的制备方法
TWI848092B (zh)	2019-04-03	2024-07-11	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白調節劑
US11873300B2 (en)	2019-08-14	2024-01-16	Vertex Pharmaceuticals Incorporated	Crystalline forms of CFTR modulators
TWI899097B (zh)	2019-08-14	2025-10-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
WO2021030556A1 (en)	2019-08-14	2021-02-18	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2021156811A1 (en) *	2020-02-05	2021-08-12	Laurus Labs Limited	Novel processes for preparation of tezacaftor
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2022036060A1 (en)	2020-08-13	2022-02-17	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
EP3970718A1 (en)	2020-09-18	2022-03-23	Charité - Universitätsmedizin Berlin	New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators
WO2022076620A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373974A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
MX2023004072A (es)	2020-10-07	2023-07-05	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
BR112023006470A2 (pt)	2020-10-07	2023-09-26	Vertex Pharma	Moduladores de regulador de condutância transmembrana de fibrose cística
WO2022076628A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076627A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US12612416B2 (en)	2020-10-07	2026-04-28	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230382924A1 (en)	2020-10-07	2023-11-30	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
TW202233635A (zh)	2020-10-07	2022-09-01	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
MX2023006770A (es)	2020-12-10	2023-08-14	Vertex Pharma	Metodos de tratamiento para fibrosis quistica.
CN119095597A (zh)	2022-02-03	2024-12-06	弗特克斯药品有限公司	治疗囊性纤维化的方法
US20250320226A1 (en)	2022-02-03	2025-10-16	Vertex Pharmaceuticals Incorporated	Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
CA3251045A1 (en)	2022-02-08	2023-08-17	Vertex Pharmaceuticals Incorporated	MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR IN CYSTIC FIBROSIS
PE20250606A1 (es)	2022-04-06	2025-02-26	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
AU2023273614A1 (en)	2022-05-16	2024-11-07	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
US20250340568A1 (en)	2022-05-16	2025-11-06	Vertex Pharmaceuticals Incorporated	Solid forms of a macrocyclic compounds as cftr modulators and their preparation
CN121194965A (zh)	2023-05-31	2025-12-23	奎米卡新特缇卡股份有限公司	盐酸奥扎莫德的无定形形式和晶型
IL327468A (en)	2023-10-04	2026-05-01	Vertex Pharma	Solid forms of cystic fibrosis transmembrane conductance regulator
CN122374316A (zh)	2023-10-04	2026-07-10	弗特克斯药品有限公司	囊性纤维化跨膜传导调控因子的调节剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5994341A (en)	1993-07-19	1999-11-30	Angiogenesis Technologies, Inc.	Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
CA2881078C (en)	2004-06-24	2018-10-02	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
JP5420395B2 (ja)	2006-04-07	2014-02-19	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセット輸送体の調節剤
UA104876C2 (uk) *	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
KR20160013251A (ko) *	2008-11-06	2016-02-03	버텍스 파마슈티칼스 인코포레이티드	Ａｔｐ-결합 카세트 수송자의 조절자

2008
- 2008-11-12 KR KR1020167000956A patent/KR20160013251A/ko not_active Ceased
- 2008-11-12 MX MX2013012665A patent/MX357497B/es unknown
- 2008-11-12 EP EP08876364.4A patent/EP2365972B1/en active Active
- 2008-11-12 RS RS20150170A patent/RS53868B1/sr unknown
- 2008-11-12 EP EP14197820.5A patent/EP2940016A1/en not_active Withdrawn
- 2008-11-12 JP JP2011535544A patent/JP5600322B2/ja active Active
- 2008-11-12 AU AU2008363828A patent/AU2008363828B2/en active Active
- 2008-11-12 CA CA2742821A patent/CA2742821C/en active Active
- 2008-11-12 SI SI200831394T patent/SI2365972T1/sl unknown
- 2008-11-12 CN CN2008801326311A patent/CN102272127A/zh active Pending
- 2008-11-12 PT PT08876364T patent/PT2365972E/pt unknown
- 2008-11-12 KR KR1020157006518A patent/KR101587389B1/ko active Active
- 2008-11-12 KR KR1020117012764A patent/KR101559963B1/ko active Active
- 2008-11-12 UA UAA201312737A patent/UA121188C2/uk unknown
- 2008-11-12 MX MX2011004832A patent/MX2011004832A/es active IP Right Grant
- 2008-11-12 CN CN201711204617.5A patent/CN108117546A/zh active Pending
- 2008-11-12 BR BRPI0823228A patent/BRPI0823228B8/pt active IP Right Grant
- 2008-11-12 HR HRP20150288TT patent/HRP20150288T1/hr unknown
- 2008-11-12 WO PCT/US2008/012689 patent/WO2010053471A1/en not_active Ceased
- 2008-11-12 ME MEP-2015-37A patent/ME02105B/me unknown
- 2008-11-12 PL PL08876364T patent/PL2365972T3/pl unknown
- 2008-11-12 NZ NZ609962A patent/NZ609962A/en unknown
- 2008-11-12 DK DK08876364.4T patent/DK2365972T3/en active
- 2008-11-12 NZ NZ592694A patent/NZ592694A/xx not_active IP Right Cessation
- 2008-11-12 ES ES08876364.4T patent/ES2532753T3/es active Active
2011
- 2011-05-05 IL IL212737A patent/IL212737A/en active Pre-grant Review Request
- 2011-05-09 CL CL2011001027A patent/CL2011001027A1/es unknown
- 2011-05-26 ZA ZA2011/03883A patent/ZA201103883B/en unknown
2013
- 2013-12-25 RU RU2013157877/04A patent/RU2013157877A/ru not_active Application Discontinuation
2014
- 2014-07-28 IL IL233837A patent/IL233837A/en active IP Right Grant
- 2014-08-15 JP JP2014165547A patent/JP5728611B2/ja active Active
2015
- 2015-03-03 CY CY20151100222T patent/CY1116067T1/el unknown
- 2015-04-06 JP JP2015077925A patent/JP5905620B2/ja active Active
- 2015-06-30 IL IL239713A patent/IL239713A/en active Protection Beyond IP Right Term
2016
- 2016-03-16 JP JP2016052743A patent/JP2016147887A/ja active Pending
- 2016-04-15 HK HK16104342.9A patent/HK1216526A1/en unknown
2019
- 2019-03-13 HU HUS1900015C patent/HUS1900015I1/hu unknown
- 2019-03-15 FR FR19C1017C patent/FR19C1017I2/fr active Active
- 2019-03-21 LU LU00110C patent/LUC00110I2/fr unknown
- 2019-03-21 LT LTPA2019505 patent/LTC2365972I2/lt unknown
- 2019-04-04 NO NO2019015C patent/NO2019015I1/no unknown
- 2019-04-29 NL NL300984C patent/NL300984I9/nl unknown
- 2019-04-30 CY CY2019023C patent/CY2019023I1/el unknown

Also Published As

Publication number	Publication date
NZ592694A (en)	2013-05-31
IL212737A (en)	2014-08-31
AU2008363828A1 (en)	2010-05-14
WO2010053471A8 (en)	2011-09-22
WO2010053471A1 (en)	2010-05-14
JP2012507580A (ja)	2012-03-29
CL2011001027A1 (es)	2012-03-02
FR19C1017I2 (fr)	2019-07-19
MX357497B (es)	2018-07-11
IL212737A0 (en)	2011-07-31
SI2365972T1 (sl)	2015-04-30
CN102272127A (zh)	2011-12-07
HK1216526A1 (en)	2016-11-18
LTC2365972I2 (lt)	2019-12-10
AU2008363828B2 (en)	2016-09-08
BRPI0823228B1 (pt)	2020-10-20
KR20150036819A (ko)	2015-04-07
EP2365972B1 (en)	2014-12-17
FR19C1017I1 (fr)	2019-05-03
ZA201103883B (en)	2012-02-29
NL300984I9 (nl)	2019-05-15
HRP20150288T1 (hr)	2015-04-24
JP2014208719A (ja)	2014-11-06
ES2532753T3 (es)	2015-03-31
CA2742821A1 (en)	2010-05-14
RU2011122461A (ru)	2012-12-20
IL233837A (en)	2015-07-30
BRPI0823228B8 (pt)	2021-05-25
PT2365972E (pt)	2015-03-31
PL2365972T3 (pl)	2015-05-29
JP2015127345A (ja)	2015-07-09
KR101587389B1 (ko)	2016-01-28
DK2365972T3 (en)	2015-01-19
LUC00110I1 (pt)	2019-03-25
JP5728611B2 (ja)	2015-06-03
CY2019023I2 (el)	2019-11-27
KR101559963B1 (ko)	2015-10-26
NO2019015I1 (no)	2019-04-04
RS53868B1 (sr)	2015-08-31
IL239713A0 (en)	2015-08-31
LTPA2019505I1 (lt)	2019-04-10
EP2940016A1 (en)	2015-11-04
NZ609962A (en)	2014-11-28
JP2016147887A (ja)	2016-08-18
RU2512682C2 (ru)	2014-04-10
HUS1900015I1 (hu)	2019-05-28
CN108117546A (zh)	2018-06-05
JP5600322B2 (ja)	2014-10-01
EP2365972A1 (en)	2011-09-21
HK1162477A1 (en)	2012-08-31
KR20110082188A (ko)	2011-07-18
KR20160013251A (ko)	2016-02-03
UA121188C2 (uk)	2020-04-27
CY1116067T1 (el)	2017-02-08
IL233837A0 (en)	2014-09-30
LUC00110I2 (pt)	2020-07-10
CA2742821C (en)	2018-10-23
CY2019023I1 (el)	2019-11-27
NL300984I2 (nl)	2019-05-02
RU2013157877A (ru)	2015-06-27
IL239713A (en)	2017-10-31
ME02105B (me)	2015-10-20
JP5905620B2 (ja)	2016-04-20
MX2011004832A (es)	2011-07-28

Legal Events

Date	Code	Title	Description
2016-10-18	B15I	Others concerning applications: loss of priority	Free format text: OBSERVA-SE QUE AS PRIORIDADES REQUERIDAS US 61/112,152 DE 06.11.2008 E 61/112,145 DE 06.11.2008 POSSUEM DEPOSITANTE DIFERENTE DO INFORMADO NA ENTRADA NA FASE NACIONAL E SUAS RESPECTIVAS CESSOES FORAM APRESENTADAS EM 11/11/2011 APOS O PRAZO REGULAR DE 60 DIAS DA ENTRADA NA FASE NACIONAL QUE SE ENCERRAVA EM 05/07/2011, MOTIVO PELO QUAL SERA DADA PERDA DESTAS PRIORIDADES, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O.
2017-02-07	B12F	Other appeals [chapter 12.6 patent gazette]
2018-03-13	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2020-02-18	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-03-03	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-08-11	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-10-20	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
BRPI0921234A2 (pt)	2016-02-23	moduladores de cassete de ligação a atp
LTC2365972I2 (lt)	2019-12-10	ATF surišančios kasetės transporterių moduliatoriai
KR101949907B9 (ko)	2023-08-16	유체-밸런싱 카세트
BRPI0813653A2 (pt)	2014-12-30	Compostos de imidazotiazol moduladores de sirtuína
BRPI0815717A2 (pt)	2015-02-10	Compostos de imidazopirazina.
BRPI0813651A2 (pt)	2014-12-30	Compostos de tiazolopiridina moduladores de sirtuína
ZA201102454B (en)	2012-01-25	Pesticidal combinations containing sulfoxaflor
BRPI0820743A2 (pt)	2015-06-16	Carretel de função
ITTO20080627A1 (it)	2009-03-27	Innesto a frizione a dischi multipli.
DE602008002287D1 (de)	2010-10-07	Aufzeichnungsgerät
IT1396065B1 (it)	2012-11-09	Innesto a frizione a dischi multipli.
GB0709145D0 (en)	2007-06-20	Information handling
ZA200905531B (en)	2010-04-28	Pesticidal Combinations
GB0724874D0 (en)	2008-01-30	Turntable laser
IT1393413B1 (it)	2012-04-20	Composizione pesticida.
DE602008002037D1 (de)	2010-09-16	Aufzeichnungsgerät
ZA201000803B (en)	2011-04-28	Pesticidal combinations
GB0717315D0 (en)	2007-10-17	Cassette
BRPI0818773A2 (pt)	2015-04-14	Moduladores de gama-secretase ligados a carbono
IT1393582B1 (it)	2012-04-27	Composizione pesticida.
GB0720008D0 (en)	2007-11-21	A pyrotechnic cassette
DE502006005852D1 (de)	2010-02-25	Anleger
DE602006013353D1 (de)	2010-05-12	Hologramm-rekorder
DE502008001426D1 (de)	2010-11-11	Abdeckanordnung
ITBO20060671A1 (it)	2008-03-30	Termocopertura flessibile a maglie.